Johnson & Johnson Innovation | Janssen Business Development seeks to identify collaborative opportunities that will create transformative value for our partners and the world.
Driving Collaborative Innovation to Accelerate Breakthroughs
The Janssen Business Development team focuses on mid- and late-stage collaborations with established pharmaceutical and biotechnology companies to accelerate breakthrough innovation to solve unmet medical needs and create real value in Janssen’s six defined therapeutic areas. We are very active in acquiring assets, companies, and technologies as well as entering into strategic collaborations, licenses, profit splits, and commercial partnerships.
The Janssen Business Development team has a proven, positive track record of deal performance. We are focused on genuine collaborations and take a thoughtful approach to risk-taking. No two deals are exactly alike, and we spend the time to understand the unique needs of our partners and optimize deal structures tailored to maximize value for all parties.
Our goal is to form active partnerships where we can bring the full strength of Johnson & Johnson to bear to create a lasting and valuable relationship. Our direct access to decision makers within Johnson & Johnson allows for creative and timely problem solving, and we integrate deal makers with science leaders from the very beginning to optimize success.
If you represent the appropriate type of company, seek a collaboration or merger and acquisition discussions, or have a compound that has shown proof of concept in humans, make the connection with Johnson & Johnson Innovation, Janssen Business Development.
